Beverly Hills Private Wealth LLC Buys Shares of 22,156 Becton, Dickinson and Company $BDX

Beverly Hills Private Wealth LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 22,156 shares of the medical instruments supplier’s stock, valued at approximately $3,353,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the fourth quarter worth about $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at about $29,000. WPG Advisers LLC raised its stake in shares of Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 61 shares during the period. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $32,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,779 shares of company stock valued at $1,974,669 in the last three months. 0.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Barclays increased their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Finally, Piper Sandler lifted their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $183.16 on Monday. The company has a market cap of $50.47 billion, a P/E ratio of 55.17, a PEG ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average price is $157.84 and its 200 day moving average price is $161.41.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.